or Try an Advanced Search...

    Clinical Development Stocks List

    Symbol Grade Name % Change
    XTLB C XTL Biopharmaceuticals Ltd. -0.38
    SRPT C Sarepta Therapeutics, Inc. 4.35
    REGN C Regeneron Pharmaceuticals, Inc. 1.06
    ALNY C Alnylam Pharmaceuticals, Inc. -1.07
    NBIX C Neurocrine Biosciences, Inc. -0.91
    GH C Guardant Health, Inc. -1.35
    ICLR D ICON plc 0.59
    BBIO D BridgeBio Pharma, Inc. -2.91
    AEZS D AEterna Zentaris Inc. -2.42
    NXTC D NextCure, Inc. -2.53
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices
    Related Stock Lists: Biopharmaceutical Biotechnology Life Sciences Medicine Alcohol Clinical Trial Diabetes Disorders Drug Discovery Drugs Immune System Monoclonal Antibodies Pharmaceutical Schizophrenia Anemia Antibodies Antidepressants Antineoplastic Drugs Antipsychotic Autoimmune Disease

    Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 6.25
    GERM B ETFMG Treatments Testing and Advancements ETF 5.57
    BTEC D Principal Healthcare Innovators Index ETF 5.34
    XPH D SPDR S&P Pharmaceuticals ETF 4.86
    PILL F Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 4.07
    View all Clinical Development ETFs...
    Compare ETFs
    Compare BBP to GERM Compare BTEC to XPH Compare GERM to PILL

        Clinical Development Stocks Recent News

        Date Stock Title
        May 31 SRPT Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
        May 31 REGN FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
        May 31 REGN FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
        May 31 GH Guardant Health Named to TIME100 Most Influential Companies
        May 31 REGN Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
        May 31 ICLR Icon PLC (ICLR) Soars 4.3%: Is Further Upside Left in the Stock?
        May 31 REGN Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
        May 31 REGN Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
        May 30 NXTC NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
        May 30 ICLR Do Options Traders Know Something About ICON (ICLR) Stock We Don't?
        May 30 GH Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
        May 30 ICLR ICON Hosts Investor Day and Updates Full Year 2024 Financial Guidance
        May 30 REGN Biohaven doses first subject in Phase I/II tumour treatment study
        May 30 SRPT Sarepta Therapeutics set to join S&P MidCap 400
        May 30 GH Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
        May 29 AEZS Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
        May 29 SRPT Sarepta Therapeutics Set to Join S&P MidCap 400
        May 29 BBIO BridgeBio reports additional positive data for acoramidis in ATTR-CM
        May 29 NBIX Neurocrine Biosciences to Participate at Investor Conferences in June
        May 29 BBIO Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Information Technology Services Medical Devices
        Related Stock Lists: Biopharmaceutical Cancer Medicine Drugs Life Sciences Solid Tumors Amyloid Amyloidosis Autoimmune Disease Blastoma Lymphoma Organ Systems Peptides Prostate Cancer Transthyretin Achondroplasia Acute Intermittent Porphyria Acute Myeloid Leukemia Alcohol Alnylam Pharmaceuticals
        Clinical Development

        Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

        Browse All Tags